Humacyte, Inc. (NASDAQ:HUMA) Given Consensus Recommendation of "Buy" by Analysts

Shares of Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) have been assigned a consensus recommendation of "Buy" from the eight research firms that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $13.71.

Several analysts have commented on HUMA shares. HC Wainwright reaffirmed a "buy" rating and issued a $15.00 price objective on shares of Humacyte in a research report on Wednesday, March 12th. D. Boral Capital reiterated a "buy" rating and issued a $25.00 price objective on shares of Humacyte in a research note on Wednesday, March 26th. Finally, Benchmark reissued a "buy" rating on shares of Humacyte in a research report on Thursday, February 27th.

Insider Transactions at Humacyte

In other news, Director Kathleen Sebelius purchased 50,000 shares of the stock in a transaction dated Tuesday, April 8th. The shares were purchased at an average cost of $1.32 per share, with a total value of $66,000.00. Following the completion of the acquisition, the director now owns 91,207 shares in the company, valued at $120,393.24. This represents a 121.34 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Dale A. Sander acquired 20,000 shares of the business's stock in a transaction dated Thursday, April 10th. The stock was purchased at an average price of $1.53 per share, with a total value of $30,600.00. Following the completion of the transaction, the chief financial officer now directly owns 40,600 shares of the company's stock, valued at $62,118. This trade represents a 97.09 % increase in their position. The disclosure for this purchase can be found here. Insiders purchased 83,993 shares of company stock valued at $118,224 over the last three months. Company insiders own 11.20% of the company's stock.

Institutional Trading of Humacyte

Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in shares of Humacyte by 10.8% in the fourth quarter. Vanguard Group Inc. now owns 5,602,684 shares of the company's stock worth $28,294,000 after purchasing an additional 543,995 shares during the period. Barclays PLC increased its stake in Humacyte by 177.6% in the 3rd quarter. Barclays PLC now owns 236,742 shares of the company's stock worth $1,288,000 after acquiring an additional 151,458 shares during the last quarter. Brookstone Capital Management bought a new position in Humacyte in the 4th quarter worth about $56,000. Wealth Effects LLC raised its stake in Humacyte by 89.1% in the fourth quarter. Wealth Effects LLC now owns 121,400 shares of the company's stock valued at $613,000 after purchasing an additional 57,200 shares in the last quarter. Finally, KLP Kapitalforvaltning AS bought a new stake in shares of Humacyte during the 4th quarter worth $99,000. 44.71% of the stock is currently owned by hedge funds and other institutional investors.

Humacyte Stock Down 5.5 %

HUMA stock opened at $1.37 on Wednesday. The firm has a market cap of $212.51 million, a PE ratio of -1.02 and a beta of 1.62. The business has a 50 day moving average of $2.51 and a 200-day moving average of $3.98. Humacyte has a 12-month low of $1.15 and a 12-month high of $9.97.

Humacyte (NASDAQ:HUMA - Get Free Report) last announced its earnings results on Friday, March 28th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.07. The business had revenue of $7.23 million for the quarter, compared to analysts' expectations of $0.64 million. On average, research analysts expect that Humacyte will post -1.27 earnings per share for the current year.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.